Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Alliance Grants

University of Guelph

$108,000.00

Developing, standardizing, and assessing a GMP grade cultivation system for psychedelic mushrooms

FY 2024-25

Summary
Psychedelic mushrooms have gained significant interest from the medical community based on early data showing positive responses in a range of mental health disorders that currently lack effective treatments. In response, Health Canada has facilitated access to psychedlics through the Special Access Program (SAP). However, all materials accessed through this program must be produced under good manufacturing practices (GMP), a system developed in the pharmaceutical world to ensure safety and efficacy of pharmaceuticals. While GMP systems are well developed for the production of traditional pharmaceutical compounds, they are less defined for chemically complex and highly variable whole mushroom products and there is currently very little information on how psychedelic mushrooms can and should be cultivated to meet the intentions and requirements of GMP. The main objective of this project will be to establish and evaluate a highly controlled and reproducible cultivation system for psychedelic muchrooms that will be capable to producing high quality, and chemically consistent muchroom biomass for further research and commercialization. Specifically, we propose to move away from traditional grain based cultivation systems that present problems with uniformity, microbial contamination, and potential pesticide residue, and develop a completely sterile cultivation system using a synthetic substrate. This system will be further optimized by comparing multiple genotypes, optimizing stage of development, and the optimal storage conditions. Together, this will provide a well defined platform for GMP compliant mushroom production. In the second phase of this project, different mushrooms will be evaluated in a pre-clinical model delivering the same amount of psilocybin to determine the importance of other compounds on the biological effect and explore the mode of actions at a deeper level.Overall, this project will establish standards for the production of GMP compliant mushroom biomass, thereby improving the safety and efficacy of the psychedelic mushroom supply.
Program
Alliance Grants
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
591025-2023
Name nom
Jones, Andrew AM
Department département
Plant Agriculture (Guelph)
Organization id
24
Institution établissement
University of Guelph
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2024
Competition year année de concours
2023
Award amount
108000
Program id
ALLRP
Program name en
Alliance Grants
Program name fr
Subventions Alliance
Group en
RESEARCH PARTNERSHIPS
Group fr
PARTENARIATS DE RECHERCHE
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1209
Area of application group en
Advancement of knowledge
Area of application group fr
Avancement des connaissances
Area of application en
Agriculture
Area of application fr
Agriculture
Research subject code
5205
Research subject group en
Microbiology
Research subject group fr
Microbiologie
Research subject en
Mycology
Research subject fr
Mycologie
Field of research list names en
Not available
Field of research list names fr
Non disponible
Socioeconomic objective list names en
Not available
Socioeconomic objective list names fr
Non disponible
Application title
Developing, standardizing, and assessing a GMP grade cultivation system for psychedelic mushrooms
Keywords
axenic; cultivation; good manufacturing practices; mushroom; mycology; neuroplasticity; psilocybin; psychedelics; secondary metabolism
Application summary
Psychedelic mushrooms have gained significant interest from the medical community based on early data showing positive responses in a range of mental health disorders that currently lack effective treatments. In response, Health Canada has facilitated access to psychedlics through the Special Access Program (SAP). However, all materials accessed through this program must be produced under good manufacturing practices (GMP), a system developed in the pharmaceutical world to ensure safety and efficacy of pharmaceuticals. While GMP systems are well developed for the production of traditional pharmaceutical compounds, they are less defined for chemically complex and highly variable whole mushroom products and there is currently very little information on how psychedelic mushrooms can and should be cultivated to meet the intentions and requirements of GMP. The main objective of this project will be to establish and evaluate a highly controlled and reproducible cultivation system for psychedelic muchrooms that will be capable to producing high quality, and chemically consistent muchroom biomass for further research and commercialization. Specifically, we propose to move away from traditional grain based cultivation systems that present problems with uniformity, microbial contamination, and potential pesticide residue, and develop a completely sterile cultivation system using a synthetic substrate. This system will be further optimized by comparing multiple genotypes, optimizing stage of development, and the optimal storage conditions. Together, this will provide a well defined platform for GMP compliant mushroom production. In the second phase of this project, different mushrooms will be evaluated in a pre-clinical model delivering the same amount of psilocybin to determine the importance of other compounds on the biological effect and explore the mode of actions at a deeper level.Overall, this project will establish standards for the production of GMP compliant mushroom biomass, thereby improving the safety and efficacy of the psychedelic mushroom supply.